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Abstract
Background and Objective Short-term fasting can alter
drug exposure but it is unknown whether this is an effect of
altered oral bioavailability and/or systemic clearance.
Therefore, the aim of our study was to assess the effect of
short-term fasting on oral bioavailability and systemic
clearance of different drugs.
Methods In a randomized, controlled, crossover trial, 12
healthy subjects received a single administration of a
cytochrome P450 (CYP) probe cocktail, consisting of
caffeine (CYP1A2), metoprolol (CYP2D6), midazolam
(CYP3A4), omeprazole (CYP2C19) and warfarin
(CYP2C9), on four occasions: an oral (1) and intravenous
(2) administration after an overnight fast (control) and an
oral (3) and intravenous (4) administration after 36 h of
fasting. Pharmacokinetic parameters of the probe drugs
were analyzed using the nonlinear mixed-effects modeling
software NONMEM.
Results Short-term fasting increased systemic caffeine
clearance by 17% (p = 0.04) and metoprolol clearance by
13% (p\ 0.01), whereas S-warfarin clearance decreased
by 19% (p\ 0.01). Fasting did not affect bioavailability.
Conclusion The study demonstrates that short-term fasting
alters CYP-mediated drug metabolism in a non-uniform
pattern without affecting oral bioavailability.
Key Points
Short-term fasting influences systemic drug
metabolism mediated by cytochrome P450 (CYP)
1A2, CYP2C9 and CYP2D6 but did not affect oral
bioavailability.
The effect of fasting is enzyme specific since short-
term fasting affected systemic clearance in a non-
uniform pattern.
Additional research is warranted to determine if dose
adjustments of drugs metabolized by CYP are
necessary to improve drug treatment in patients with
fasting-related consequences, such as malnutrition,
or in combination with diets based on therapeutic
fasting.
1 Introduction
The ultimate goal of personalized medicine is to predict the
best treatment strategy for the individual patient. To
achieve this, it is necessary to understand the factors that
contribute to variability within and between patients, which
remains a challenge [1]. There is considerable variability in
drug metabolism, which may result in treatment failure or,
conversely, in untoward side effects. Cytochrome P450
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(CYP) enzymes play an important role in drug metabolism
since this enzyme family catalyzes the oxidative phase I
biotransformation of most drugs [2]. Whereas monogenic
polymorphisms explain an important part of the variability
for a few CYP enzymes, most enzymes are multifactorially
controlled by genetic, physiologic, pharmacologic, envi-
ronmental, and nutritional factors such as fasting [3].
Short-term fasting can modulate the activity of some
CYP enzymes in preclinical studies and in humans [4–8].
In a previous study, we have demonstrated that short-term
fasting increased clearance of caffeine by 20% but
decreased clearance of S-warfarin by 25%, when admin-
istered in an oral cocktail of five different drugs [8]. This
cocktail consisted of the following CYP probes: caffeine
(CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4),
omeprazole (CYP2C19), and warfarin (CYP2C9) [9].
Together, these enzymes account for more than 70% of all
phase I-dependent metabolism of drugs, nutraceuticals, and
herbal remedies [3].
CYP enzymes not only reside in the liver but also in the
gastrointestinal tract. CYP3A4 is abundantly expressed in
the small intestine and, to a lesser extent, CYP1A2,
CYP2C9, CYP2C19 and CYP2D6 [10]. The intestinal
metabolism by CYP3A substrates is often similar to, or
even exceeds, hepatic metabolism even though the total
content of, for example, CYP3A in the entire human small
intestine is only 1% of that in the liver [11]. In our previous
study, the drug cocktail was administered orally. It is
unknown whether the effects of fasting on drug metabolism
were caused by altered oral bioavailability and/or altered
systemic clearance. Therefore, the aim of our current study
was to assess the effect of short-term fasting on oral
bioavailability and systemic clearance by using the cocktail
approach in healthy volunteers.
2 Materials and Methods
2.1 Subjects
Twelve healthy male subjects were recruited to participate
in the trial. Inclusion criteria were as follows: (1) age
18 years or older; and (2), healthy, as determined by an
experienced physician, and with normal renal and liver
function. Exclusion criteria were (1) major illness in the
past 3 months; (2) gastrointestinal disease that may influ-
ence drug absorption; (3) abnormal values of the following
laboratory parameters: alanine aminotransferase, alkaline
phosphatase, aspartate aminotransferase, bilirubin, c-glu-
tamyl transferase, and creatinine; (4) excessive alcohol
intake (more than three units of alcohol per day) or use of
alcohol for at least 2 days prior to each study day; (5) drugs
of abuse; (6) smokers; (7) strenuous exercise at least 3 days
prior to each study day, defined as more than 1 h of
exercise per day; (8) use of prescription or nonprescription
drugs; (9) consumption of caffeine-containing foods or
beverages within 1 day prior to the study; and (10) con-
sumption of grapefruit and grapefruit-containing products
or starfruit for at least 2 days prior to each study day [8].
2.2 Study Design
We performed an open-label, randomly assigned, crossover
intervention study in healthy male subjects. After approval
of the protocol (Amendment 2, ABRnr: NL40834.018.12)
by the Institutional Ethics Review Board, this study was
performed at the Academic Medical Center, University of
Amsterdam, The Netherlands. Each subject received a
single oral or intravenous administration of a drug cocktail
on four occasions, with washout periods of 4 weeks: an
oral (1) or intravenous (2) administration after an overnight
fast (control), and an oral (3) or intravenous (4) adminis-
tration after 36 h of fasting. Subjects were randomly
assigned for the order in which they received the drug
cocktail. On all occasions, the drug cocktail was adminis-
tered at 8:00 a.m. In order to minimize the effect of food
intake in the morning on the bioavailability of the drug
cocktail, subjects fasted from 10:00 p.m. the preceding
evening while participating in the control interventions
[occasions (1) and (2)]. In the fasting interventions [occa-
sions (3) and (4)], subjects fasted from 8:00 p.m. starting
two evenings prior to administration of the cocktail. This
ensures a period of 36 h of fasting at the time of admin-
istration of the cocktail. On each of the four occasions,
subjects had a standard fluid meal (Nutridrink Compact;
Nutricia, Zoetermeer, The Netherlands) at noon. The meal
was standardized to prevent differences in caloric intake
between the interventions to affect the pharmacokinetics of
the drug cocktail. After 4:00 p.m. subjects were allowed to
consume their habitual diet [8].
Subjects kept a diary containing dietary instructions to
standardize their diet in the 3 days preceding each of the
four occasions. Furthermore, the following biomarkers
were measured at baseline on each occasion in order to
check adherence to the fasting protocol: glucose, b-hy-
droxybutyrate, free fatty acids, and acetoacetate [12].
2.3 Cytochrome P450 (CYP) Probe Cocktail
Subjects received a CYP probe drug cocktail that had
previously been validated by Turpault et al. and consisted
of caffeine (CYP1A2), metoprolol (CYP2D6), midazolam
(CYP3A4), omeprazole (CYP2C19), and S-warfarin
(CYP2C9) [9]. The cocktail administered orally consisted
of caffeine 100 mg (10 mg/mL, 1 mL ampoules; VU
University Medical Center [VUMC], Amsterdam, The
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Netherlands), racemic warfarin 5 mg (5 mg tablet; Cres-
cent Pharma Ltd, Hampshire, UK), omeprazole 20 mg
(20 mg capsule; Teva Pharmachemie, Haarlem, The
Netherlands), metoprolol 100 mg (100 mg tablet; Teva
Pharmachemie), and midazolam 0.03 mg kg-1 (1 mg/mL
oral solution; University Medical Centre Groningen,
Groningen, The Netherlands) [8]. The intravenous admin-
istration of the cocktail consisted of caffeine 50 mg
(10 mg/mL, 1 mL ampoules; VUMC), racemic warfarin
5 mg (5 mg/mL, 3 mL ampoules; Radboud University
Medical Center, Nijmegen, The Netherlands), omeprazole
20 mg (40 mg powder for solution for infusion; AstraZe-
neca BV, Zoetermeer, The Netherlands), metoprolol 20 mg
(1 mg/mL, 5 mL ampoules; AstraZeneca BV), and mida-
zolam 0.015 mg kg-1 (5 mg/mL, 1 mL ampoules; Roche
Nederland BV, Woerden, The Netherlands).
2.4 Blood Sampling and Bioanalysis of the CYP
Probe Drugs
For the estimation of pharmacokinetic parameters, blood
samples were collected pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8
and 10 h after oral administration of the drug cocktail. For
the intravenous treatment arms, samples were taken pre-
dose and at 2, 11.5, 15, 29, 41.5, 60, 90, 135, 173, 180,
195 min and 3.5, 4, 5, 7 and 9 h after intravenous admin-
istration of the drug cocktail blood. Furthermore, pharma-
cokinetic samples were obtained at days 2, 3, 8 and 15, of
which the latter two were due to the long elimination half-
life of warfarin [13]. Plasma was separated by centrifuga-
tion and stored at -80 C until analysis.
The plasma concentrations of the drugs in the cocktail
were simultaneously determined using a validated liquid
chromatography/tandem mass spectrometry (LC-MS/MS)
method as previously described [14]. The lower and upper
limits of quantification (LLOQ and ULOQ) were
50–5000 ng mL-1 for caffeine, 1–200 ng mL-1 for meto-
prolol, 0.5–100 ng mL-1 for midazolam, 2–500 ng mL-1
for omeprazole, and 4–1000 ng mL-1 for S-warfarin. Lin-
earity was R2 C 0.995 for all components. For all analytes,
the mean process efficiency was[95% and the mean ion-
ization efficiency was[97%. Furthermore, for all analytes
the accuracy was between 94.9 and 108%, and the within-
and between-run imprecision was\11.7% for the LLOQ and
\12.6% for the middle level and ULOQ [14].
2.5 Pharmacogenetic Analysis
Genomic DNA was isolated from whole blood using a total
nucleic acid extraction kit on a MagnaPure LC (Roche
Diagnostics GmbH, Penzberg, Germany). Genotyping was
performed using predesigned DME Taqman allelic dis-
crimination assays on the Life Technologies Taqman 7500
system. Each assay consisted of two allele-specific minor
groove binding (MGB) probes, labeled with the fluorescent
dyes VIC and FAM. Polymerase chain reactions (PCRs)
were performed in a reaction volume of 10 lL, containing
assay-specific primers, allele-specific TaqmanMGB probes,
Abgene Absolute QPCR Rox Mix, and genomic DNA
(20 ng). The thermal profile consisted of 40 cycles of
denaturation at 95 C for 20 s and annealing at 92 C for 3 s,
aswell as extension at 60 C for 30 s.Genotypeswere scored
by measuring allele-specific fluorescence using the 7500
software v2.3 for allelic discrimination (Applied Biosys-
tems, Thermo Fisher Scientific, Waltham, MA, USA):
CYP1A2 -3860G[A (*1C allele), -163C[A (*1F and *1K
alleles), -729C[T (*1K allele); for CYP2C9 430C[T (*2)
and 1075A[C (*3); for CYP3A4 -392A[G (*1B),
g.20230G[A (*1G), 664T[C (*2), 1334T[C (*3), 352A[G
(*4), 653G[C (*5), 520G[C (*10), 1117C[T (*12),
566T[C (*17), 878T[C (*18) and g.15389C[T (*22).
CYP2C19 and CYP2D6 were analyzed on INFINITY Plus
(Autogenomics, San Diego, CA, USA) according to the
manufacturer’s instructions. For CYP2C19, variants ana-
lyzed were 681G[A (*2), 636G[A (*3), 1A[G (*4),
1297C[T (*5), 395G[A (*6), g.19294T[A (*7), 358T[C
(*8), 431G[A (*9), 680C[T (*10) and -806C[T (*17); for
CYP2D6, 2-1584C[G (*2), 2549delA (*3), 1846G[A (*4),
gene deletion (*5), 1707delT (*6), 2935A[C (*7), 1758G[T
(*8), 2615_2617delAAG (*9), 100C[T (*4, *10), 124G[A
(*14), 1023C[T (*17), 1659G[A (*29), 2988G[A (*41)
and gene duplication. The absence of investigated single
nucleotide polymorphisms (SNPs) gave the default allele
assignment ‘‘*1’’.
2.6 Pharmacokinetic Analysis
Data were analyzed using the first-order conditional esti-
mation with interaction (FOCE-I) method in the nonlinear
mixed-effects modeling software NONMEM version 7.2
(Globomax LLC, Hanover, MD, USA). Nonlinear mixed-
effects compartmental modeling was preferred instead of
noncompartmental analysis because of the ability to
accurately study the time-dependent effects of fasting on
the pharmacokinetics of the probe drugs [8]. Furthermore,
NONMEM allows to study only the variability between
both interventions (i.e. the effect of fasting versus the
control intervention) without incorporating other factors
that may bias this variability, such as time-based interoc-
casion variability [15].
2.6.1 Structural Model
The concentration data were log-transformed for all com-
pounds; one-, two-, and three-compartment models were
fitted to the data. The population models were built in a
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stepwise manner. The following parameters were quantified:
clearance (CL), intercompartment clearance (Q), and vol-
ume of distribution of the central (V1) and peripheral com-
partment (V2). For caffeine, midazolam and S-warfarin the
absorption rate constant (Ka) could not be estimated and was
fixed to 6 h-1. In order to account for the delay between
administration of omeprazole and absorption from the gut,
also known as transit time, transit compartments were
incorporated in the omeprazole pharmacokineticmodel [16].
The mean transit time (MTT) between the gut and systemic
circulation was estimated by dividing the ratio of the number
of transit compartments (n) by the transition rate constant
(Ktr) between the compartments (MTT = n/Ktr) [16].
For all parameter estimates, inter- and intraindividual
variability were assessed assuming a log-normal distribu-
tion and an exponential error model [8, 15]. Residual
variability was estimated with an additional error model.
Software such as R version 64 3.0.1 (The R Foundation
for Statistical Computing, Vienna, Austria) and Xpose
version 4 (Uppsala University, Dept. of Pharmaceutical
Biosciences, Uppsala, Sweden) were used to visualize and
evaluate the models [17]. Pirana software (Pirana Software
& Consulting BV, Denekamp, The Netherlands) was used
as an interface between NONMEM, R and Xpose [18].
The log-likelihood ratio test was used to discriminate
between different structural and statistical models. A
reduction in the objective function value (OFV) of C3.9
points was considered statistically significant (p\ 0.05 for
one degree of freedom) [15]. In addition, goodness-of-fit
plots (population or individual predictions versus obser-
vations of measured drug concentrations, and conditional
weighted residuals (CWRES) versus time and population
predictions) and g and e shrinkage were assessed [19].
Furthermore, the confidence interval (CI) of the parameter
estimates, the correlation matrix, and visual improvement
of the individual plots were used to evaluate the model. Ill-
conditioning was assessed by the ratio between the largest
and smallest eigenvalue of the covariance matrix of the
estimate from the NONMEM output. A ratio of [1000
indicates ill-conditioning of the model and is often due to
overparameterization [20].
2.6.2 Covariate Analysis
The effect of fasting on pharmacokinetic parameters, sys-
temic clearance (CL), bioavailability (F), and volume of
distribution (V) was evaluated by stepwise inclusion in the
models [8, 21].
In order to study a possible time dependency of fasting
on the pharmacokinetics of the drugs in the cocktail, a time
cut-point covariate model was used in which the pharma-
cokinetic parameter was increased or decreased due to
fasting before the time cut-point (hcut) and comparable with
the control intervention after hcut [8]. The effect of fasting
was tested for one pharmacokinetic parameter at a time and
statistically tested by the likelihood ratio test. When fasting
significantly affected more than one parameter, the model
with the largest decrease in the OFV was chosen as the
basis to sequentially explore the influence of additional
parameters. The final model containing the effect of fasting
was further evaluated as discussed in the structural model
section.
2.6.3 Model Validation
To evaluate validity and robustness of the final models,
simulation-based diagnostics (visual predictive checks
[VPCs]) and bootstrap diagnostics were used [22, 23]. The
bootstrap analysis was performed using the Perl modules
Pearl-speaks-NONMEM. The model-building dataset was
resampled 1000 times to create new datasets similar in size
[22, 24]. Parameter estimates obtained by the bootstrap
analysis (median values and the 2.5th and 97.5th per-
centiles of parameter distribution) were compared with the
parameter estimates of the final pharmacokinetic models.
VPC plots were used to compare the 10th and 90th per-
centiles of simulated concentration–time profiles (1000
replicates) with the observed concentrations [23].
2.7 Statistical Analysis
A paired t test (normally distributed data) and a Wilcoxon
signed-rank test (not normally distributed data) were used
to test differences in biochemical parameters between the
occasions, and the Shapiro–Wilk test was used to assess the
normality of data distribution. A p-value B0.05 was con-
sidered significant. Statistical analysis was performed using
IBM SPSS Statistics version 23.0 (IBM Corporation,
Armonk, NY, USA).
3 Results
3.1 Healthy Subjects and Study Design
Twelve healthy male subjects (mean age 23.6 years) were
recruited to participate in the trial. Eight subjects com-
pleted all four interventions. This study was based on an
amendment of our previously published study in which
nine subjects received the cocktail orally [8]. Of these nine
subjects, six also received the cocktail intravenously. In
addition, the data of the other three subjects who received
the drug cocktail on the two occasions after oral adminis-
tration, and the data of one other subject who completed
the two intravenous interventions plus one oral interven-
tion, were included to further optimize the models.
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No adverse events were reported, and baseline charac-
teristics are shown in Table 1.
DNA for the analysis of CYP1A2, CYP2C9, CYP2C19,
CYP2D6, and CYP3A4 polymorphisms was available in
nine subjects. The distribution of genotypes are shown in
Table 1. Subjects were characterized as either extensive
metabolizers (EMs, normal CYP enzyme activity) and/or
intermediate metabolizers (IMs, slightly reduced CYP
enzyme activity compared with EMs) for CYP1A2,
CYP2C9, CYP2C19 and CYP3A4. For CYP2D6, one
subject was characterized genotypically as a poor
metabolizer (PM, little or no CYP2D6 enzyme activity)
and another subject was characterized as an ultra-rapid
metabolizer (UM, multiple copies of the CYP2D6 gene
and therefore increased CYP2D6 enzyme activity)
(Table 1).
After 36 h of fasting, the biomarkers for fasting (glu-
cose, c-hydroxybutyrate, free fatty acids, and acetoacetate)
were all significantly altered in comparison with the control
condition, which indicates compliance to the fasting pro-
tocol (Table 2).
3.2 Pharmacokinetics of CYP Probe Drugs
The pharmacokinetics of the five probe drugs after both
oral and intravenous administration were characterized by
nonlinear mixed-effects modeling (NONMEM). The data
of all 12 subjects included in the trial were used to develop
pharmacokinetic models. Since not all subjects received
the four administrations, this may introduce an unbalanced
design. However, one of the advantages of NONMEM over
noncompartmental analysis is the effective way of incor-
porating an unbalanced design [25]. Therefore, this does
not preclude accurate analysis of the effect of fasting
within subjects. The plasma concentration versus time
profiles were described using a one-compartment model for
caffeine, a two-compartment model for metoprolol and
omeprazole, and a three-compartment model for metopro-
lol and S-warfarin (Table 3).
3.2.1 Model Validation
The observed data were described well by the developed
models, as demonstrated by the goodness-of-fit plots
(Fig. 1). Furthermore, no trends were observed in the plots
of CWRES versus time or model-predicted concentrations
(plots not shown). The g and e shrinkage of the pharma-
cokinetic parameters and residual variability were\20%.
Table 3 gives an overview of the parameter estimates of
the final models and the nonparametric bootstraps
(n = 1000 replicates per model). As the latter were in
agreement with those of the final pharmacokinetic models,
the parameter estimates of the final models are considered
reliable. VPC plots further demonstrate the validity of the
models since the central tendency and variability of the
simulated data is comparable with the observed data
(Fig. 2).
3.2.2 Effect of Fasting on Oral Bioavailability
and Systemic Clearance
3.2.2.1 Caffeine (CYP1A2) Although restricted by the
study protocol, preadministration plasma concentrations of
caffeine were observed (range 0–709 mg/L). To account
for this variable pre-intake of caffeine, we incorporated a
fictive caffeine dose of 100 mg orally or 50 mg intra-
venously, with variable bioavailability in the model that
was administered 12 h before administration of the cock-
tail. The typical bioavailability and its interoccasion vari-
ability of this pre-intake were estimated in the NONMEM
analysis. The mean pre-intake of caffeine was low since the
Table 1 Baseline characteristics
Patient characteristics Median (range)
Age, years 23 (19–33)
Height, cm 186 (175–194)
Body weight, kg 80 (68–103)
Ethnicity [n = 12] Caucasian
Genotype [n = 9] n (%)
CYP1A2
*1A/*1F (EM) 5 (56)
*1F/*1F (EM) 4 (44)
CYP2C9
*1/*1 (EM) 1 (11)
*1/*2 (IM) 5 (56)
*1/*3 (IM) 3 (33)
CYP2C19
*1/*1 (EM) 2 (22)
*1/*2 (IM) 4 (44)
*1/*4 (IM) 1 (11)
*1/*8 (IM) 1 (11)
*1/*17 (EM) 1 (11)
CYP2D6
*1/*1 (EM) 1 (11)
*1/*1 (xN) (UM) 1 (11)
*1/*2 (EM) 1 (11)
*1/*3 (IM) 1 (11)
*1/*4 (IM) 4 (44)
*4/*4 (PM) 1 (11)
CYP3A4
*1A/*1A (EM) 9 (100)
EM extensive metabolizer, IM intermediate metabolizer, PM poor
metabolizer, UM ultra-rapid metabolizer, xN allele duplication
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typical bioavailability was 4.0%, whereas the variability
was high (1250%) due to three subjects with observed
caffeine plasma concentrations at baseline.
The typical subject had a systemic caffeine clearance
(CLcaffeine) of 6.67 L/h. Fasting increased CLcaffeine by 17%
(hCL,fasting = 1.17, 95% CI 1.06–1.28, p = 0.04) (Table 3).
The accompanying VPC plot also illustrates this effect
(Fig. 2A1, B1). After post hoc analysis, 36 h of fasting
increased the median caffeine clearance after oral admin-
istration (CLPO-caffeine,posthoc) from 6.67 L/h (range
3.71–11.52) in the control group to 8.09 L/h (range
3.95–17.47). After intravenous administration, fasting
increased the median post hoc caffeine clearance (CLIV-
caffeine,posthoc) from 6.80 L/h (range 3.37–11.91) in the
control group to 7.29 L/h (range 4.91–10.56) (Fig. 3A1,
B1). Furthermore, 36 h of fasting decreased the central
volume of distribution (V1) by 9% (V1,caffeine = 0.91, 95%
CI 0.83–0.99, p = 0.01). Fasting did not affect the oral
bioavailability of caffeine (Fcaffeine) (Table 3).
3.2.2.2 Metoprolol (CYP2D6) For two subjects, the
exposure of metoprolol clearly deviated from the other
subjects based on the plasma concentration–time curves.
Both subjects were also characterized genotypically as a
CYP2D6 PM (CYP2D6 *4/*4) and UM (CYP2D6 *1/
*xN1), respectively (Table 1). Systemic CLmetoprolol was
65.8 L/h for the typical subject, but 56% lower for the PM.
Furthermore, typical bioavailability of metoprolol was 45%
and was more than twofold higher in this subject. For the
UM, CLmetoprolol was doubled and bioavailability (FUR)
was lower, with a value of 19%. Estimation of the differ-
ence in bioavailability and clearance of the PM and UM
significantly improved the final model of metoprolol based
on OFV (DOFV = -87.6), but also led to ill-conditioning.
Therefore, bioavailability and clearance of the PM and UM
were determined using a similar NONMEM model that
only included the data of the control intervention without
taking the effect of fasting into account, and both param-
eters were then FIXED in the final model.
Fasting increased systemic CLmetoprolol by 13% (hCL,-
fasting = 1.13, 95% CI 1.06–1.20, p\ 0.01), but did not
affect oral bioavailability of metoprolol (Fmetoprolol)
(Table 3; Fig. 2A2, B2). Following oral administration of
metoprolol, short-term fasting increased the median post
hoc estimates for systemic clearance from 65.7 L/h (range
28.6–143.4) after the control intervention to 92.7 L/h
(range 29.5–144.2) after 36 h of fasting. After intravenous
administration, short-term fasting increased the median
metoprolol clearance (CLIV-metoprolol,posthoc) from 75.2 L/h
(range 27.1–119.8) to 86.2 L/h (range 31.8–148.2)
(Fig. 3A2, B2).
3.2.2.3 Midazolam (CYP3A4) The systemic clearance
(CLmidazolam) or oral bioavailability (Fmidazolam) of mida-
zolam was not affected by fasting (Table 3; Fig. 2A3, B3).
Median post hoc estimates for systemic midazolam clear-
ance after oral administration were 24.3 L/h (range
16.3–30.0) after the control intervention and 22.87 L/h
(range 16.75–33.89) after 36 h of fasting. Following
intravenous administration, the median clearance of
midazolam (CLIV-midazolam,posthoc) after the control inter-
vention was 24.43 L/h (range 23.56–33.34) and 24.29 L/h
(range 16.27–29.96) after 36 h of fasting (Fig. 3A3, B3).
3.2.2.4 Omeprazole (CYP2C19) Since omeprazole is
known to show a delay (transit time) between administra-
tion and absorption from the gut, we incorporated 10 transit
compartments in the model [16]. The MTT was 1.6 h, with
an intraindividual variability of 23% (Table 3).
Omeprazole systemic clearance (CLomeprazole) or oral
bioavailability (Fomeprazole) were not affected by fasting
(Table 3; Fig. 2A4, B4). Median post hoc estimates for
clearance following oral administration were 14.02 L/h
(range 9.20–24.50) and 16.00 L/h (range 8.36–19.54) after
the control intervention and 36 h of fasting, respectively.
After intravenous administration of omeprazole, the med-
ian clearance was 14.27 L/h (range 10.03–21.93) after the
control intervention and 13.80 L/h (range 11.65–23.54 L/
h) after 36 h of fasting (Fig. 3A4, B4).
3.2.2.5 S-Warfarin (CYP2C9) Estimation of oral
bioavailability (FS-warfarin) resulted in an approximate value
Table 2 Effect of 36 h of fasting on biochemical parameters in healthy subjects
Value Oral administration [n = 11] Intravenous administration [n = 9]
Control Fasting (36 h) p-Value Control Fasting (36 h) p-Value
Glucose, mmol/l 5.07 (4.60–5.90) 4.05 (3.60–5.10) 0.011 4.97 (4.40–5.40) 4.40 (3.60–5.00) 0.024
b-Hydroxybutyrate, mmol/l 0.11 (0.00–0.40) 0.69 (0.30–1.60) 0.005 0.10 (0.00–0.20) 0.83 (0.30–2.70) 0.011
Acetoacetate, mmol/l 0.05 (0.01–0.15) 0.19 (0.08–0.33) 0.005 0.05 (0.01–0.09) 0.25 (0.06–0.80) 0.012
Free fatty acids, mmol/l 0.49 (0.15–0.91) 1.03 (0.60–1.55) 0.018 0.48 (0.19–0.73) 1.29 (0.63–2.57) 0.012
Data are expressed as median (range)
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Effect of Fasting on Drug Metabolism
of FS-warfarin % 1, indicating that bioavailability after oral
administration is circa 100%, which is also described in the
literature [13]. Since estimation of bioavailability did not
improve the model, this parameter was fixed to FS-
warfarin = 1.
Until 14 h after cocktail administration, fasting
decreased S-warfarin systemic clearance by 19% compared
with the control group (hCL,fasting = 0.81, 95% CI
0.67–0.96, p\ 0.01). Fasting also decreased the central
volume of distribution by 21% (hV1,fasting = 0.79, 95% CI
0.75–0.84, p\ 0.001); the corresponding time cut-point
was 25 h (Table 3; Fig. 2A5, B5). As both CL and V1
decreased at approximately the same amount, an effect of
fasting on bioavailability may also explain the result after
oral administration of the cocktail. However, similar results
were found after intravenous administration of the cocktail,
which indicates that bioavailability does not play a role.
After post hoc analysis, short-term fasting decreased the
median systemic S-warfarin clearance following oral
administration from 0.19 L/h (range 0.12–0.31) after the
control intervention to 0.16 L/h (range 0.12–0.25) after
36 h of fasting. After intravenous administration of war-
farin, fasting decreased the median clearance from 0.20 L/
h (range 0.16–0.31) after the control intervention to 0.17 L/
h (range 0.14–0.26) after 36 h of fasting (Fig. 3A5, B5).
4 Discussion
In this crossover intervention study, we determined the
effects of short-term fasting on oral bioavailability and sys-
temic clearance related to CYP-mediated drug metabolism
in healthy subjects, and found that short-term fasting
increased systemic clearance of caffeine and metoprolol.
This indicates that fasting increased the activity of CYP1A2
and CYP2D6, considering that caffeine and metoprolol are
probes for the activity of these enzymes, respectively. Fur-
thermore, short-term fasting decreased systemic S-warfarin
clearance, which indicates decreased activity of CYP2C9,
considering that S-warfarin is a probe of CYP2C9 activity.
Although short-term fasting affected systemic clearance
mediated by several CYP enzymes, fasting did not affect oral
bioavailability of the five CYP probe drugs. The drug
cocktail used has previously been validated by Turpault et al.
[9]. The absence of a pharmacokinetic interaction between
the probe drugs makes this cocktail useful for the in vivo
evaluation of metabolism-based interactions [9].
The effects of fasting on systemic clearance of caffeine
and S-warfarin are in line with our previous findings that
short-term fasting alters oral clearance of both drugs in a
non-uniform pattern [8]. We can now confirm that fasting
affects systemic clearance rather than an effect on oral
bioavailability. In contrast to our previous study, short-T
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Fig. 1 Goodness-of-fit plots of
the five CYP probe drugs.
Observed concentrations versus
population-predicted (left panel)
and individual-predicted (right
panel) concentrations:
a caffeine (CYP1A2);
b metoprolol (CYP2D6);
c midazolam (CYP3A4);
d omeprazole (CYP2C19); e S-
warfarin (CYP2C9). The closed
circles represent the 36 h of
fasting intervention and the
open circles represent the
control intervention. The solid
line is the line of identity. CYP
cytochrome P450, conc
concentration
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Fig. 2 Visual predictive check
plots of the five CYP probe
drugs after oral [left panel (1)]
and intravenous [right panel
(2)] administration: a caffeine
(CYP1A2); b metoprolol
(CYP2D6); c midazolam
(CYP3A4); d omeprazole
(CYP2C19); e S-warfarin
(CYP2C9). The closed circles
represent the observed data
points after 36 h of fasting and
the open circles represent the
control observations. The solid
(36 h fasting) and dashed
(control) lines represent the 10th
and 90th percentiles of the
simulated data. CYP
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term fasting also altered metoprolol clearance, which is
likely due to increased statistical power because of a larger
sample size.
Estimation of the difference in bioavailability between
the control and the fasting intervention with NONMEM did
not improve the models. However, we were able to
estimate bioavailability of the probe drugs for the typical
subject, and the results are all in agreement with the pro-
duct characteristics of the drugs: Fcaffeine & 0.97, Fmeto-
prolol & 0.45, Fmidazolam & 0.35, Fomeprazole & 0.44, and
Fs-warfarin & 1.0 [13]. This strengthens our conclusion that
no effect of short-term fasting on bioavailability was found.
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Despite the study restrictions, pre-intake plasma con-
centrations of caffeine were observed at baseline, which
may question the compliance to the protocol regarding the
other fasting-related restrictions. Compliance to the fasting
protocol was tested by measuring biomarkers for fasting
(glucose, b-hydroxybutyrate, free fatty acids, and ace-
toacetate) before administration of the cocktail at each
intervention. For all subjects, short-term fasting readily
changed the plasma concentrations of these biomarkers,
which indicates compliance to the fasting protocol.
Subjects were genotyped for the CYP1A2, CYP2C9,
CYP2C19, CYP2D6, and CYP3A4 polymorphisms
(Table 1). For metoprolol only, the genotype improved the
model. However, the randomized crossover design in
which each subject serves as his own control enabled us to
only study the effect of fasting, instead of a mixture of
other factors that may also influence drug metabolism, such
as genotype, and physiologic and environmental factors.
Although the data acquisition in this randomized, con-
trolled, crossover intervention study was sufficiently dense
and individuals served as their own controls, NONMEM
was preferred over noncompartmental analysis because of
its ability to accurately study time-dependent effects of
fasting on the pharmacokinetics of the probe drugs. This
was based on recently reported findings of a variable time-
dependent effect of fasting on S-warfarin clearance that
diminished when returned to the nonfasting state [8]. The
observation of the caffeine pre-intake at baseline further
strengthens our choice for NONMEM since we were able
to account for this variable pre-intake of caffeine, thereby
excluding this type of bias (this would not have been
possible when using noncompartmental analysis).
In addition to the potential effects on oral bioavailabil-
ity, drug clearance can also be affected by differences in
protein binding. The observed differences in clearance of
caffeine, metoprolol, and S-warfarin may therefore not
only be an effect of fasting on intrinsic clearance but also
on protein binding, as described by the well-stirred model
of drug metabolism (Eqs. 1 and 2) [26]:
CL ¼ QH  ðfu  CLintÞ =ðQH þ fu  CLintÞ ð1Þ
CL ¼ QH  EH ð2Þ
where QH indicates hepatic blood flow, fu indicates fraction
of unbound drug in plasma, CLint indicates intrinsic
clearance of unbound drug, and EH indicates the hepatic
extraction ratio.
For drugs with a low extraction ratio (EH\ 0.3), such as
caffeine (fu % 0.65) and S-warfarin (fu % 0.01), the hep-
atic clearance can mainly be influenced by changes in
protein binding and intrinsic clearance [27]. We have
shown that fasting increased caffeine clearance but
decreased S-warfarin clearance in a non-uniform pattern. If
fasting affects protein binding, we would have expected a
similar pattern for both drugs. Therefore, it is more likely
that the observed effect of fasting on caffeine and S-war-
farin clearance is based on intrinsic clearance caused by
differences in CYP enzyme activity. In addition, this non-
uniform pattern in drug clearance is in line with the
expression of hepatic messenger RNA (mRNA) of the
corresponding CYP enzymes in rat [8].
Following intravenous administration of drugs with an
intermediate extraction ratio (EH = 0.3–0.7), such as
metoprolol (EH = 0.67), midazolam (EH = 0.31), and
omeprazole (EH = 0.35), drug clearance can be affected by
changes in a combination of three determinants: QH, CLint,
and fu [13, 27]. We have shown that fasting increases
metoprolol clearance but it is unlikely that this is caused by
an effect of fasting on QH or fu instead of CLint. The
fraction of unbound metoprolol is already high (90–95%)
and therefore is not likely to be significantly affected by
fasting [13]. Furthermore, it is unlikely that fasting would
have increased hepatic blood flow to retrieve the observed
effect since the opposite has been described in literature
[28, 29]. Additional research needs to be performed to
study the effect of fasting on protein binding.
Our findings imply that dosage adjustments of drugs
metabolized by CYP enzymes could be necessary to
improve drug treatment in patients with malnutrition.
Recently, studies have shown that short-term fasting can
have a positive effect on the treatment of cancer [30–32].
By short-term fasting, the susceptibility to chemotherapy
can differ between healthy somatic and cancer cells, a
phenomenon called differential stress resistance [30].
Because it is likely that the effects of short-term fasting
will be enhanced if the period of fasting is prolonged,
clinical trials are now being performed in the field of
oncology, with low protein fasting mimicking diets to ease
the burden of prolonged fasting [31, 33]. In order to opti-
mize drug treatment, it would be of interest to study not
only the effect of these diets on differential stress resistance
but also to study the effect of the fasting-based diet on the
metabolism of the drugs that are administered during this
diet, especially for drugs with a small therapeutic range
and/or metabolized by the specific CYP enzymes that were
affected by fasting (CYP1A2, CYP2D6, and CYP2C9), e.g.
bendamustine, cyclophosphamide, flutamide, gefitinib,
idarubicin, or tamoxifen [13, 34].
Although more preclinical than clinical research has
been performed to study the pharmacological mechanism
behind our findings, the exact mechanism of action of
fasting still remains unsolved. Nuclear receptors such as
the pregnane X receptor (PXR) and constitutive androstane
receptor (CAR) regulate the activity of many of the drug-
metabolizing CYP enzymes [35]. The fact that fasting
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differentially affects CYP enzymes showing either
increased (CYP1A2, CYP2D6) or decreased (CYP2C9)
activity indicates a complex interplay of different factors
that regulate CYP enzyme activity.
5 Conclusion
Our study provides evidence that short-term fasting alters
systemic clearance of CYP-mediated drug metabolism but
does not affect changes in oral bioavailability of drugs.
Additional research is warranted to study the clinical
implications of our findings.
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